Cardiovascular Drugs Market 2027 By Drug Class, Distribution Channel and Geography | The Insight Partners

Cardiovascular Drugs Market to 2027 - Global Analysis and Forecasts by Drug Class (Anti-Hypertensive, Anti-Hyperlipidemics, Anti-Coagulants, Anti-Arrhythmic, Anti-Fibrinolytic, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

Report Code: TIPRE00004427 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Cardiovascular diseases (CVD) is a class of diseases that involve conditions affecting the heart or blood vessels. Drugs are a primary medication used to control various parameters in the cardiovascular diseases. Some of the major diseases for which cardiovascular drugs are recommended by the doctor includes inflammatory heart disease, heart failure, angina and others.

MARKET DYNAMICS
The cardiovascular drugs market is anticipated to grow in the forecast, owing to increasing incidence of cardiovascular diseases across the globe, adoption of sedentary lifestyle and rising geriatric population. In addition, development of novel drugs by market players through strategic collaboration is expected to offer significant growth opportunities in the market during the forecast period.

MARKET SCOPE
The "Global Cardiovascular Drugs Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of cardiovascular drugs market with detailed market segmentation by drug class, distribution channel and geography. The global cardiovascular drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading cardiovascular drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global cardiovascular drugs market is segmented on the basis of by drug class and distribution channel. Based on drug class, the market is segmented as, anti-hypertensive, anti-hyperlipidemics, anti-coagulants, anti-arrhythmic, anti-fibrinolytic, others. Based on distribution channel, the market is segmented in to hospital pharmacies, retail pharmacies, and online pharmacies.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global cardiovascular drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The cardiovascular drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting cardiovascular drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the cardiovascular drugs market in these regions.

MARKET PLAYERS
The reports cover key developments in the cardiovascular drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from cardiovascular drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for cardiovascular drugs market in the global market. Below mentioned is the list of few companies engaged in the cardiovascular drugs market.

The report also includes the profiles of key cardiovascular drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Pfizer Inc.
  • Bayer AG
  • Novartis AG
  • Merck KGaA
  • Abbott
  • Sun Pharmaceutical Industries Ltd.
  • Gilead Sciences Inc.
  • Takeda Pharmaceutical Company Ltd
  • Eli Lily and Company
  • Johnson & Johnson Services, Inc.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Cardiovascular Drugs Market - By Drug Class
1.3.2 Cardiovascular Drugs Market - By Distribution Channel
1.3.3 Cardiovascular Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. CARDIOVASCULAR DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CARDIOVASCULAR DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CARDIOVASCULAR DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. CARDIOVASCULAR DRUGS - GLOBAL MARKET OVERVIEW
6.2. CARDIOVASCULAR DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. CARDIOVASCULAR DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. ANTI-HYPERTENSIVE
7.3.1. Overview
7.3.2. Anti-Hypertensive Market Forecast and Analysis
7.4. ANTI-HYPERLIPIDEMICS
7.4.1. Overview
7.4.2. Anti-Hyperlipidemics Market Forecast and Analysis
7.5. ANTI-COAGULANTS
7.5.1. Overview
7.5.2. Anti-Coagulants Market Forecast and Analysis
7.6. ANTI-ARRHYTHMIC
7.6.1. Overview
7.6.2. Anti-Arrhythmic Market Forecast and Analysis
7.7. ANTI-FIBRINOLYTIC
7.7.1. Overview
7.7.2. Anti-Fibrinolytic Market Forecast and Analysis
7.8. OTHERS
7.8.1. Overview
7.8.2. Others Market Forecast and Analysis
8. CARDIOVASCULAR DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. ONLINE PHARMACIES
8.5.1. Overview
8.5.2. Online Pharmacies Market Forecast and Analysis
9. CARDIOVASCULAR DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Cardiovascular Drugs Market Overview
9.1.2 North America Cardiovascular Drugs Market Forecasts and Analysis
9.1.3 North America Cardiovascular Drugs Market Forecasts and Analysis - By Drug Class
9.1.4 North America Cardiovascular Drugs Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Cardiovascular Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Cardiovascular Drugs Market
9.1.5.1.1 United States Cardiovascular Drugs Market by Drug Class
9.1.5.1.2 United States Cardiovascular Drugs Market by Distribution Channel
9.1.5.2 Canada Cardiovascular Drugs Market
9.1.5.2.1 Canada Cardiovascular Drugs Market by Drug Class
9.1.5.2.2 Canada Cardiovascular Drugs Market by Distribution Channel
9.1.5.3 Mexico Cardiovascular Drugs Market
9.1.5.3.1 Mexico Cardiovascular Drugs Market by Drug Class
9.1.5.3.2 Mexico Cardiovascular Drugs Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Cardiovascular Drugs Market Overview
9.2.2 Europe Cardiovascular Drugs Market Forecasts and Analysis
9.2.3 Europe Cardiovascular Drugs Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Cardiovascular Drugs Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Cardiovascular Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Cardiovascular Drugs Market
9.2.5.1.1 Germany Cardiovascular Drugs Market by Drug Class
9.2.5.1.2 Germany Cardiovascular Drugs Market by Distribution Channel
9.2.5.2 France Cardiovascular Drugs Market
9.2.5.2.1 France Cardiovascular Drugs Market by Drug Class
9.2.5.2.2 France Cardiovascular Drugs Market by Distribution Channel
9.2.5.3 Italy Cardiovascular Drugs Market
9.2.5.3.1 Italy Cardiovascular Drugs Market by Drug Class
9.2.5.3.2 Italy Cardiovascular Drugs Market by Distribution Channel
9.2.5.4 Spain Cardiovascular Drugs Market
9.2.5.4.1 Spain Cardiovascular Drugs Market by Drug Class
9.2.5.4.2 Spain Cardiovascular Drugs Market by Distribution Channel
9.2.5.5 United Kingdom Cardiovascular Drugs Market
9.2.5.5.1 United Kingdom Cardiovascular Drugs Market by Drug Class
9.2.5.5.2 United Kingdom Cardiovascular Drugs Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Cardiovascular Drugs Market Overview
9.3.2 Asia-Pacific Cardiovascular Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Cardiovascular Drugs Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Cardiovascular Drugs Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Cardiovascular Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Cardiovascular Drugs Market
9.3.5.1.1 Australia Cardiovascular Drugs Market by Drug Class
9.3.5.1.2 Australia Cardiovascular Drugs Market by Distribution Channel
9.3.5.2 China Cardiovascular Drugs Market
9.3.5.2.1 China Cardiovascular Drugs Market by Drug Class
9.3.5.2.2 China Cardiovascular Drugs Market by Distribution Channel
9.3.5.3 India Cardiovascular Drugs Market
9.3.5.3.1 India Cardiovascular Drugs Market by Drug Class
9.3.5.3.2 India Cardiovascular Drugs Market by Distribution Channel
9.3.5.4 Japan Cardiovascular Drugs Market
9.3.5.4.1 Japan Cardiovascular Drugs Market by Drug Class
9.3.5.4.2 Japan Cardiovascular Drugs Market by Distribution Channel
9.3.5.5 South Korea Cardiovascular Drugs Market
9.3.5.5.1 South Korea Cardiovascular Drugs Market by Drug Class
9.3.5.5.2 South Korea Cardiovascular Drugs Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Cardiovascular Drugs Market Overview
9.4.2 Middle East and Africa Cardiovascular Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Cardiovascular Drugs Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Cardiovascular Drugs Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Cardiovascular Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Cardiovascular Drugs Market
9.4.5.1.1 South Africa Cardiovascular Drugs Market by Drug Class
9.4.5.1.2 South Africa Cardiovascular Drugs Market by Distribution Channel
9.4.5.2 Saudi Arabia Cardiovascular Drugs Market
9.4.5.2.1 Saudi Arabia Cardiovascular Drugs Market by Drug Class
9.4.5.2.2 Saudi Arabia Cardiovascular Drugs Market by Distribution Channel
9.4.5.3 U.A.E Cardiovascular Drugs Market
9.4.5.3.1 U.A.E Cardiovascular Drugs Market by Drug Class
9.4.5.3.2 U.A.E Cardiovascular Drugs Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Cardiovascular Drugs Market Overview
9.5.2 South and Central America Cardiovascular Drugs Market Forecasts and Analysis
9.5.3 South and Central America Cardiovascular Drugs Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Cardiovascular Drugs Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Cardiovascular Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Cardiovascular Drugs Market
9.5.5.1.1 Brazil Cardiovascular Drugs Market by Drug Class
9.5.5.1.2 Brazil Cardiovascular Drugs Market by Distribution Channel
9.5.5.2 Argentina Cardiovascular Drugs Market
9.5.5.2.1 Argentina Cardiovascular Drugs Market by Drug Class
9.5.5.2.2 Argentina Cardiovascular Drugs Market by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. CARDIOVASCULAR DRUGS MARKET, KEY COMPANY PROFILES
11.1. PFIZER INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. BAYER AG
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. NOVARTIS AG
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. MERCK KGAA
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. ABBOTT
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. SUN PHARMACEUTICAL INDUSTRIES LTD.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. GILEAD SCIENCES INC.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. TAKEDA PHARMACEUTICAL COMPANY LTD
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. ELI LILY AND COMPANY
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. JOHNSON AND JOHNSON SERVICES, INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Pfizer Inc.
2. Bayer AG
3. Novartis AG
4. Merck KGaA
5. Abbott
6. Sun Pharmaceutical Industries Ltd.
7. Gilead Sciences Inc.
8. Takeda Pharmaceutical Company Ltd
9. Eli Lily and Company
10. Johnson & Johnson Services, Inc.